SANTA CLARA, Calif. / May 13, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for the first quarter ended March 31, 2025.
First Quarter & Subsequent 2025 Operational Highlights
The Company continues to make significant progress towards commercial readiness with key clinical and regulatory achievements on the HeartBeam System.
VALID-ECG Pivotal Study:
12-Lead ECG Synthesis Software FDA Submission:
Commercial Readiness Plans:
Other Highlights:
Management Commentary
“The first quarter of 2025 demonstrated continued progress on commercial readiness plans, underscored by successful pivotal study results, a new strategic partnership, and strengthened intellectual property protection,” said Robert Eno, Chief Executive Officer, HeartBeam.
“Since submitting a 510(k) application to the FDA for the 12-lead ECG synthesis software designed for the assessment of arrhythmias, we have had ongoing productive discussions with the FDA. The submission is backed by robust data demonstrating HeartBeam successfully met the clinical endpoints in the VALID-ECG pivotal study. This important milestone confirms that our technology has the ability to deliver 12-lead ECG-like insights through the convenience of a credit card-sized device that patients can use whenever arrhythmia symptoms occur.
“We recently partnered with AccurKardia, an innovator in ECG-based diagnostics technology, to add its FDA-cleared ECG analysis software, AccurECG, to our devices. We believe combining our platforms will enhance our commercial offering for arrhythmia assessment by enabling patients and physicians to get an automated rhythm assessment. This will facilitate quicker diagnosis and faster access to clinical care when needed. The strategic collaboration is expected to expedite our product development efforts, reducing both costs and timelines.
“We received two new US patents to bolster the defensive and offensive moat around our core technology. The first patent significantly advances intellectual property for our credit card-sized ECG device, and the second patent expands the use of risk-based diagnostic algorithms into our product portfolio around wearable devices. We now own 20 issued patents worldwide, cementing our leadership in cardiac monitoring innovation.
“Looking ahead, we are focused on commercial readiness activities and key growth milestones, leveraging gross proceeds of approximately $11.5 million from the recent fundraising we completed during the quarter. With productive discussions with the FDA on our 12-lead ECG synthesis software submission, we believe our timeline for clearance remains intact. We also commenced initial FDA interactions on expanding our indication to include ischemia and acute coronary events such as heart attacks. We expect to start enrollment in a Pilot Study on this indication in the second half of 2025. Taken together, we are advancing steadily on our milestones and look forward to additional updates in the months to come,” concluded Eno.
First Quarter 2025 Financial Results
Research and development expenses for the first quarter of 2025 were $3.5 million, compared to $2.4 million for the first quarter of 2024.
General and administrative expenses for the first quarter of 2025 were $2.0 million compared to $2.4 million for the first quarter of 2024.
Net loss for the first quarter of 2025 was $5.5 million, compared to a net loss of $4.6 million for the first quarter of 2024.
Net cash used in operating activities was $4.5 million for the three months ended March 31, 2025, as compared to $3.5 million for the first quarter of 2024.
Cash, cash equivalents, and short-term investments totaled $8.2 million as of March 31, 2025, compared to $2.4 million as of December 31, 2024. On February 25, 2025, the Company closed a public offering of common stock with gross proceeds of $11.5 million in February 2025, including the exercise of the underwriter’s over-allotment option.
First Quarter 2025 Results Conference Call
HeartBeam CEO Robert Eno and CFO Tim Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.
To access the call, please use the following information:
Date: | Tuesday, May 13, 2025 |
Time: | 4:30 p.m. Eastern time (1:30 p.m. Pacific time) |
Dial-in: | 1-844-826-3035 |
International Dial-in: | 1-412-317-5195 |
Conference Code: | 10199007 |
Webcast: |
A telephone replay will be available approximately three hours after the call and will run through August 13, 2025, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 10199007. The replay can also be viewed through the webcast link above and the presentation utilized during the call will be available in the Company’s investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
HEARTBEAM, INC. Condensed Balance Sheets (Unaudited) (In thousands, except share data) | |||||||
| March 31, |
| December 31, | ||||
Assets |
|
|
| ||||
Current Assets: |
|
|
| ||||
Cash and cash equivalents | $ | 4,390 |
|
| $ | 2,377 |
|
Short-term investments |
| 3,760 |
|
|
| — |
|
Prepaid expenses and other current assets |
| 458 |
|
|
| 393 |
|
Total Current Assets |
| 8,608 |
|
|
| 2,770 |
|
|
|
|
| ||||
Property and equipment, net |
| 443 |
|
|
| 450 |
|
Other assets |
| 56 |
|
|
| 56 |
|
Total Assets | $ | 9,107 |
|
| $ | 3,276 |
|
|
|
|
| ||||
|
|
|
| ||||
|
|
|
| ||||
Liabilities and Stockholders’ Equity |
|
|
| ||||
Current Liabilities: |
|
|
| ||||
Accounts payable (includes related party $5 and $5, respectively) | $ | 523 |
|
| $ | 531 |
|
Accrued expenses |
| 1,055 |
|
|
| 1,091 |
|
Total Current Liabilities |
| 1,578 |
|
|
| 1,622 |
|
|
|
|
| ||||
Total Liabilities |
| 1,578 |
|
|
| 1,622 |
|
|
|
|
| ||||
Commitments |
|
|
| ||||
|
|
|
| ||||
Stockholders’ Equity |
|
|
| ||||
Preferred stock - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at March 31, 2025 and December 31, 2024 |
| — |
|
|
| — |
|
Common stock - $0.0001 par value 100,000,000 shares authorized; 33,734,548 and 26,960,901 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively |
| 3 |
|
|
| 3 |
|
Additional paid in capital |
| 69,283 |
|
|
| 57,924 |
|
Accumulated deficit |
| (61,757 | ) |
|
| (56,273 | ) |
Total Stockholders’ Equity |
| 7,529 |
|
|
| 1,654 |
|
|
|
|
| ||||
Total Liabilities and Stockholders’ Equity | $ | 9,107 |
|
| $ | 3,276 |
|
HEARTBEAM, INC. Condensed Statements of Operations (Unaudited) (In thousands, except share and per share data) | |||||||
| Three months ended March 31, | ||||||
|
| 2025 |
|
|
| 2024 |
|
Operating Expenses: |
|
|
| ||||
General and administrative | $ | 2,012 |
|
| $ | 2,356 |
|
Research and development |
| 3,492 |
|
|
| 2,428 |
|
Total operating expenses |
| 5,504 |
|
|
| 4,784 |
|
|
|
|
| ||||
Loss from operations |
| (5,504 | ) |
|
| (4,784 | ) |
|
|
|
| ||||
Other Income and (Expense) |
|
|
| ||||
Interest income |
| 20 |
|
|
| 178 |
|
Total other income |
| 20 |
|
|
| 178 |
|
|
|
|
| ||||
Loss before provision for income taxes |
| (5,484 | ) |
|
| (4,606 | ) |
|
|
|
| ||||
Income tax provision |
| — |
|
|
| — |
|
|
|
|
| ||||
Net Loss | $ | (5,484 | ) |
| $ | (4,606 | ) |
|
|
|
| ||||
Net loss per share, basic and diluted | $ | (0.18 | ) |
| $ | (0.17 | ) |
|
|
|
| ||||
Weighted average common shares outstanding, basic and diluted |
| 30,378,751 |
|
|
| 26,511,201 |
|
|
|
|
|
HEARTBEAM, INC. Condensed Statements of Cash Flows (Unaudited) (In thousands) | |||||||
| Three months ended March 31, | ||||||
|
| 2025 |
|
|
| 2024 |
|
Cash Flows From Operating Activities |
|
|
| ||||
Net loss | $ | (5,484 | ) |
| $ | (4,606 | ) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
| ||||
Depreciation |
| 7 |
|
|
| — |
|
Stock based compensation expense |
| 1,109 |
|
|
| 1,207 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Prepaid expenses and other current assets |
| (65 | ) |
|
| 33 |
|
Accounts payable and accrued expenses |
| (44 | ) |
|
| (97 | ) |
Net cash used in operating activities |
| (4,477 | ) |
|
| (3,463 | ) |
|
|
|
| ||||
Cash Flows From Investing Activities |
|
|
| ||||
Purchase of property and equipment |
| — |
|
|
| (88 | ) |
Purchase of short-term investments |
| (3,760 | ) |
|
| — |
|
Net cash used in investing activities |
| (3,760 | ) |
|
| (88 | ) |
|
|
|
| ||||
Cash Flows From Financing Activities |
|
|
| ||||
Proceeds from sale of equity, net of issuance costs |
| 10,250 |
|
|
| — |
|
Net cash provided by financing activities |
| 10,250 |
|
|
| — |
|
|
|
|
| ||||
Net increase (decrease) in cash and restricted cash |
| 2,013 |
|
|
| (3,551 | ) |
Cash, cash equivalents and restricted cash – Beginning of period |
| 2,433 |
|
|
| 16,239 |
|
|
|
|
| ||||
Cash, cash equivalents and restricted cash – Ending of period | $ | 4,446 |
|
| $ | 12,688 |
|
|
|
|
| ||||
Reconciliation of cash, cash equivalents and restricted cash: |
|
|
| ||||
Cash and cash equivalents | $ | 4,390 |
|
| $ | 12,638 |
|
Restricted cash (included in other assets) |
| 56 |
|
|
| 50 |
|
Total cash, cash equivalents and restricted cash | $ | 4,446 |
|
| $ | 12,688 |
|
|
|
|
| ||||
Supplemental Disclosures of Cash Flow Information: |
|
|
| ||||
Purchase of property and equipment in accounts payable | $ | 2 |
|
| $ | — |
|
Last Trade: | US$1.24 |
Daily Change: | -0.03 -2.36 |
Daily Volume: | 65,829 |
Market Cap: | US$41.920M |
June 17, 2025 May 05, 2025 April 29, 2025 April 24, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load